Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Glenn J. Hanna et al.|JAMA Oncology|2020Cited by 350
Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated RadiotherapyHale Başak Çağlar, Aaron M. Allen, Roy B. Tishler et al.|International Journal of Radiation Oncology*Biology*Physics|2008Cited by 230
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Mena Mansour et al.|Science Immunology|2023Cited by 118
Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck CancerLaura A. Goguen, Robert I. Haddad, Marshall R. Posner et al.|Otolaryngology|2006Cited by 105
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104